Maravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance
Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million.
Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. The company’s shares closed last Wednesday at $6.13.Stay Ahead of ...
Jane Street Group LLC decreased its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) by ...
Throughout the last three months, 4 analysts have evaluated Maravai LifeSciences (NASDAQ:MRVI), offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and ...
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $5.33, but opened at $5.22. Maravai ...
Morgan Stanley lowered the firm’s price target on Maravai Lifesciences (MRVI) to $7 from $10 and keeps an Equal Weight rating on the shares following another miss and significant guidance cut.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a leading provider of critical products to enable the development of drug therapies, diagnostics, and novel vaccines, has recently been the subject ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback